top of page
INSIGHTS
We equip our clients with actionable insights drawn from meticulous analysis of data, firsthand experience, and comprehensive interviews. The contextual evidence we provide enables quick, confident decision-making. We're known for our unique ability to view opportunities and challenges from both the company's and the customer's vantage points, offering a nuanced perspective that can't be found anywhere else.
Filter
When Delivery Becomes Life Cycle Management Strategy in Biopharma: Merck’s Subcutaneous Keytruda
Merck’s subcutaneous (SC) Keytruda, FDA-approved on Sept 19, 2025, transforms cancer care delivery by replacing 30-minute infusions with 1–2 minute injections. This shift frees oncology clinic capacity, enhances patient access, and redefines value creation in immuno-oncology. By integrating delivery efficiency into strategy, Merck positions Keytruda’s SC formulation as a competitive and operational milestone in oncology’s evolving landscape.
Fraol Galan
Oct 227 min read
Mapping Missed Voices to Maximize Opportunities: The Role of Patient Journey Maps and Caregiver Perspectives in Informing Commercial Strategy
Patient journey mapping has transformed how life sciences companies understand and serve patients—but most maps miss a crucial voice: the caregiver. By expanding mapping to capture real-time, diverse patient experiences and integrating caregiver perspectives, companies can design more relevant trials, value-based products, and compelling launch narratives. Including those who guide patients through care not only humanizes development but drives adherence, satisfaction, and co
Kiara Wassoodew
Sep 105 min read
Phase 3 Isn’t Just a Regulatory Milestone: It’s the Start of Product Differentiation
Phase 3 isn’t just a regulatory milestone—it’s a product’s pseudo launch. In today’s competitive biopharma landscape, success depends on building product differentiation early, not after approval. The design of late-stage trials shapes labeling, messaging, and market access. By embedding differentiation into clinical strategy, companies can turn regulatory readiness into true commercial advantage.
Harris Kaplan
Jul 173 min read
Shortages and Slowdowns: How Pharmaceutical Tariffs Threaten Supply and Innovation
The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.
Liam Boyd
Apr 154 min read
The Growing Crisis of Drug Shortages in the United States
Drug shortages have intensified due to manufacturing delays, raw material scarcities, and geopolitical disruptions.
Piper Boss
Jan 227 min read
Weighing the Costs: The GLP-1 Dilemma in Healthcare Spending
As waistlines have expanded, so has the list of proposed solutions to the obesity crisis – yet nearly all have fallen short. Enter GLP-1s, the new heavyweight champions in the battle against obesity and diabetes. Stakeholders across the healthcare industry – from health plans and employers to pharma companies and patients – are scurrying to determine the potential ripple effects. At nearly $1,000 a month, GLP-1s like Ozempic, Wegovy, and Mounjaro are not just thinning waistl
Jeremy Cohen
May 6, 20243 min read
bottom of page